DE

latest development

News & Events

London (UK) February 4th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Vidac announces strengthening its Management Group and advancements in its clinical pipeline, financial planning, and upcoming transition to full fledge clinical stage company.  

 

Key Clinical Developments:

  • Vidac Pharma continues to advance its proprietary VDA 1102 (Tuvatexib) and VDA 1275 programs, reinforcing its position as a leader in targeted cancer and onco-dermatology therapeutics.
  • Phase 2B Trial in Actinic Keratosis: Vidac Pharma has signed an agreement with Centroderm to conduct a second Phase 2B clinical trial in Germany for highly proliferative actinic keratosis (AK). The company has already manufactured its GMP-compliant drug product and is in discussions with the European Medicines Agency (EMA) for a unique claim that could establish its treatment as a first-in-class therapy for dermatologists.
  • Cutaneous T-Cell Lymphoma (CTCL): Vidac Pharma successfully completed its Phase 2A trial, demonstrating a 50%+ objective response rate. A Phase 2B study is in preparation, leveraging new formulation improvements.
  • Breakthrough in Systemic Cancer Treatment: Originally developed as a topical therapy, VDA 1102 (Tuvatexib) has now been successfully reformulated for subcutaneous administration, enabling systemic delivery. This breakthrough significantly expands its potential applications, paving the way for treating multiple solid tumor indications.
  • Promising Results in Brain Cancer: Vidac Pharma’s innovative formulation was recently used in a compassionate treatment case for a child with a rare brain cancer. The drug successfully crossed the blood-brain barrier and was detected in therapeutic concentrations in the excised tumor just days after administration. Further testing on that same tumor organoids showed 99.6% sensitivity to the treatment, outperforming conventional chemotherapy. These promising results have led to collaborations with a leading Israeli hospital to develop clinical trials targeting brain cancer.
  • Intellectual Property & Pipeline Expansion: The company has been granted new patents for both VDA 1102 and VDA 1275, strengthening its intellectual property portfolio. VDA 1275, currently in advanced preclinical studies, remains on track for further development in 2025.

Strategic Growth & Investor Engagement

To support its continued expansion, Vidac Pharma has strengthened its management team with key industry experts. Additionally, in the coming weeks Analyst, Peter Thilo Hasler (Sphene Capital), will accompany management during a roadshow in Frankfurt, Munich, and Zurich, meeting with potential investors.

CEO Statement 

“Despite a challenging market environment, Vidac Pharma has achieved remarkable progress across multiple fronts. Our multiple advances and transition, combined with our clinical breakthroughs, positions us for significant growth. We remain committed to delivering first-in-class therapies that address urgent unmet medical needs with our Motto "The Patient in Mind" while creating substantial value for our shareholders.”

 

Vidac Pharma will be presenting at the Sachs Conference in Zurich on February 26–27, 2025. Investors interested in scheduling a meeting are encouraged to reach out.

 

For more information please contact:

Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/

investors@vidacpharma.com
+972-54-4257381

About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.

Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.